Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib.

Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, Pollaro M, Coretti NJ, Kosciuk MC, Nagele EP, Demarshall C, Freeman T, Shi Y, Guan C, Macphee CH, Wilensky RL, Nagele RG.

J Alzheimers Dis. 2013;35(1):179-98. doi: 10.3233/JAD-122254.

PMID:
23388174
[PubMed - indexed for MEDLINE]
2.
3.

Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?

McCullough PA.

Curr Atheroscler Rep. 2009 Sep;11(5):334-7. Review.

PMID:
19664375
[PubMed - indexed for MEDLINE]
4.

Darapladib.

Bui QT, Wilensky RL.

Expert Opin Investig Drugs. 2010 Jan;19(1):161-8. doi: 10.1517/13543780903501513. Review.

PMID:
20001561
[PubMed - indexed for MEDLINE]
5.

Darapladib: an emerging therapy for atherosclerosis.

Corson MA.

Ther Adv Cardiovasc Dis. 2010 Aug;4(4):241-8. doi: 10.1177/1753944710375820. Epub 2010 Jul 26. Review.

PMID:
20660537
[PubMed - indexed for MEDLINE]
6.

Phospholipase A2 enzymes and the risk of atherosclerosis.

Rosenson RS, Hurt-Camejo E.

Eur Heart J. 2012 Dec;33(23):2899-909. doi: 10.1093/eurheartj/ehs148. Epub 2012 Jul 15. Review.

PMID:
22802388
[PubMed - indexed for MEDLINE]
Free Article
7.

Phospholipase A2 inhibitors.

Garcia-Garcia HM, Serruys PW.

Curr Opin Lipidol. 2009 Aug;20(4):327-32. doi: 10.1097/MOL.0b013e32832dd4c7. Review.

PMID:
19550325
[PubMed - indexed for MEDLINE]
8.

Lipoprotein-associated phospholipase A2: a new therapeutic target.

Lonn E.

Can J Cardiol. 2010 Mar;26 Suppl A:27A-31A. Review.

PMID:
20386757
[PubMed - indexed for MEDLINE]
9.

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.

Packard CJ.

Curr Opin Cardiol. 2009 Jul;24(4):358-63. doi: 10.1097/HCO.0b013e32832bcb22. Review.

PMID:
19417639
[PubMed - indexed for MEDLINE]
10.

Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.

White H.

Curr Opin Cardiol. 2010 Jul;25(4):299-301. doi: 10.1097/HCO.0b013e32833aaa94. Review.

PMID:
20485161
[PubMed - indexed for MEDLINE]
11.

Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.

Rosenson RS.

Curr Opin Lipidol. 2010 Dec;21(6):473-80. doi: 10.1097/MOL.0b013e32833eb581. Review.

PMID:
20739882
[PubMed - indexed for MEDLINE]
12.

[Clinical role of lipoprotein-associated phospholipase A2].

Miklishanskaia SV, Liakishev AA, Kukharchuk VV.

Kardiologiia. 2013;53(3):59-70. Review. Russian.

PMID:
23548429
[PubMed - indexed for MEDLINE]
13.

Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons.

D'Andrea MR, Nagele RG.

Curr Pharm Des. 2006;12(6):677-84. Review.

PMID:
16472157
[PubMed - indexed for MEDLINE]
14.

Utility of Lp-PLA2 in lipid-lowering therapy.

Racherla S, Arora R.

Am J Ther. 2012 Mar;19(2):115-20. doi: 10.1097/MJT.0b013e3181e70d32. Review.

PMID:
20634673
[PubMed - indexed for MEDLINE]
15.

[Blood-brain barrier and Alzheimer's disease].

Kuwahara H, Nishida Y, Yokota T.

Brain Nerve. 2013 Feb;65(2):145-51. Review. Japanese.

PMID:
23399672
[PubMed - indexed for MEDLINE]
16.

The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery.

Sharma HS, Castellani RJ, Smith MA, Sharma A.

Int Rev Neurobiol. 2012;102:47-90. doi: 10.1016/B978-0-12-386986-9.00003-X. Review.

PMID:
22748826
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk